Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

Stacchiotti S, Blay JY, Rutkowski P, Gelderblom H, Falcón A, Le Cesne A, Desai J, Palmerini E, Serrano C, Ganjoo KN, D'Amato GZ, Ryan CW, Wilky BA, Ferraresi V, Saleh R, Ravi V, Razak AA, Herráez AC, Ahmed M, Bernthal NM, van de Sande M, Brahmi M, Szostakowski B, Sen J, Zeringo NA, Harrow B, Narasimhan S, Saunders A, Sharma MG, Sherman ML, Wagner AJ, Tap WD

Open source

DOI: 10.1002/cncr.70564
Published: 2026 Sep 1
Container: Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.70564,
  title = {Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.},
  author = {Stacchiotti S and Blay JY and Rutkowski P and Gelderblom H and Falcón A and Le Cesne A and Desai J and Palmerini E and Serrano C and Ganjoo KN and D'Amato GZ and Ryan CW and Wilky BA and Ferraresi V and Saleh R and Ravi V and Razak AA and Herráez AC and Ahmed M and Bernthal NM and van de Sande M and Brahmi M and Szostakowski B and Sen J and Zeringo NA and Harrow B and Narasimhan S and Saunders A and Sharma MG and Sherman ML and Wagner AJ and Tap WD},
  year = {2026},
  journal = {Cancer},
  doi = {10.1002/cncr.70564},
  url = {https://doi.org/10.1002/cncr.70564}
}

RIS

TY  - JOUR
TI  - Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.
AU  - Stacchiotti S
AU  - Blay JY
AU  - Rutkowski P
AU  - Gelderblom H
AU  - Falcón A
AU  - Le Cesne A
AU  - Desai J
AU  - Palmerini E
AU  - Serrano C
AU  - Ganjoo KN
AU  - D'Amato GZ
AU  - Ryan CW
AU  - Wilky BA
AU  - Ferraresi V
AU  - Saleh R
AU  - Ravi V
AU  - Razak AA
AU  - Herráez AC
AU  - Ahmed M
AU  - Bernthal NM
AU  - van de Sande M
AU  - Brahmi M
AU  - Szostakowski B
AU  - Sen J
AU  - Zeringo NA
AU  - Harrow B
AU  - Narasimhan S
AU  - Saunders A
AU  - Sharma MG
AU  - Sherman ML
AU  - Wagner AJ
AU  - Tap WD
PY  - 2026
JO  - Cancer
DO  - 10.1002/cncr.70564
UR  - https://doi.org/10.1002/cncr.70564
ER  -

APA

S, S., JY, B., P, R., H, G., A, F., A, L. C., J, D., E, P., C, S., KN, G., GZ, D., CW, R., BA, W., V, F., R, S., V, R., AA, R., AC, H., M, A., NM, B., M, V. D. S., M, B., B, S., J, S., NA, Z., B, H., S, N., A, S., MG, S., ML, S., AJ, W., & WD, T. (2026). Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.. Cancer. https://doi.org/10.1002/cncr.70564

Source records

pubmed · retrieved 2026-09-25T17:51:33.381Z